March Biosciences: Funding, Investors & Team (Aug 2026)
March Biosciences, Inc is a clinical-stage biotechnology firm whose aim is to revolutionize patient care for difficult hematological malignancies. Their main asset is currently undergoing Phase I trials for T-cell malignancies, which currently lack effective treatment options such as CAR-T or targeted therapy technologies. The company's research pipeline is geared towards building on these initial triumphs in order to have a broader impact on other difficult cancers.
March Biosciences has raised $41.8M across 2 funding rounds on record, the most recent a Series A of $28.4M announced in Oct 2024.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
March Biosciences Company Profile and Key Stats
Latest funding round on record: Oct 2024.
March Biosciences Funding Rounds
March Biosciences raised $13.4M in an undisclosed round announced in Nov 2023.
11 months later, a Series A of $28.4M was announced in Oct 2024.
March Biosciences Founders and Leadership Team
Contact details for the March Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →March Biosciences Funding Compared to Other Health Care Startups
March Biosciences' latest round of $28.4M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like March Biosciences in Health Care and Houston
Companies Similar to March Biosciences
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
March Biosciences Funding FAQs
What does March Biosciences do?
March Biosciences, Inc is a clinical-stage biotechnology firm whose aim is to revolutionize patient care for difficult hematological malignancies. Their main asset is currently undergoing Phase I trials for T-cell malignancies, which currently lack effective treatment options such as CAR-T or targeted therapy technologies. The company's research pipeline is geared towards building on these initial triumphs in order to have a broader impact on other difficult cancers.
How much funding has March Biosciences raised?
March Biosciences has raised $41.8M across 2 rounds on record. The most recent is a Series A of $28.4M announced in Oct 2024.
When did March Biosciences last raise funding?
March Biosciences' most recent funding round on record is a Series A of $28.4M, announced in Oct 2024.
Who founded March Biosciences?
FundedIQ lists Sarah Hein (Founder) at March Biosciences.
Where is March Biosciences headquartered?
March Biosciences is based in Houston, Texas, United States.
How many employees does March Biosciences have?
March Biosciences is in the 1-10 employee band.
How does March Biosciences' funding compare to other Health Care startups?
March Biosciences' latest round of $28.4M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's March Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for March Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.